中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 2
Feb.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(2): 392-396

Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis

DOI: 10.3969/j.issn.1001-5256.2022.02.025

  • Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150000, China

Research funding:

National Natural Science Foundation of China (81770276)

More Information
  • Corresponding author: YU Kaijiang, drkaijiang@163.com
  • Received Date: 2021-06-10
  • Accepted Date: 2021-08-26
  • Published Date: 2022-02-20
    Abstract
  •   Objective  To investigate the effect of the mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis.  Methods  A total of 24 adult male C57BL/6J mice were randomly divided into control group, control+SS-31 group, lipopolysaccharide (LPS) group, and LPS+SS-31 group, with 6 mice in each group. The mice were given intraperitoneal injection of LPS (10 mg/kg) to establish a model of sepsis and acute liver injury, followed by intraperitoneal injection of SS-31 (10 mg/kg) for treatment, and the mice in the control group were given intraperitoneal injection of an equal volume of PBS solution, followed by intraperitoneal injection of an equal volume of normal saline. After 12 hours, ELISA was used to measure the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), reactive oxygen species (ROS), superoxide dismutase (SOD), tumor necrosis factor-α (TNFα), interleukin-1β(IL-1β), and interleukin-6 (IL-6), and HE staining was used to observe liver histopathological changes. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups.  Results  Compared with the LPS group, the LPS+SS-31 group had significant reductions in the serum levels of ALT (140.05±12.22 U/L vs 102.64±8.75 U/L, P < 0.05) and AST (80.22±4.71 U/L vs 69.26±5.37 U/L, P < 0.05) and the levels of ROS (1 030.21±115.87 pg/mL vs 847.84±63.65 pg/mL, P < 0.05), TNFα (767.18±60.60 ng/mL vs 698.89±16.99 ng/mL, P < 0.05), IL-1β (29.97±1.37 ng/mL vs 26.70±3.09 ng/mL, P < 0.05), and IL-6 (59.13±7.09 pg/mL vs 49.29±3.41 pg/mL, P < 0.05) in liver tissue. Compared with the control group based on HE staining, the LPS group showed destruction of hepatic lobular structure, inflammatory cell infiltration, ambiguous intercellular space, and hepatocyte swelling, while the LPS+SS-31 group showed alleviation of inflammatory cell infiltration and hepatocyte swelling.  Conclusion  The mitochondria-targeted antioxidant SS-31 can reduce the production of ROS, downregulate the highly expressed inflammatory factors in sepsis, and alleviate sepsis-related acute liver injury in mice.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.
    [2]
    FLEISCHMANN C, SCHERAG A, ADHIKARI NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193(3): 259-272. DOI: 10.1164/rccm.201504-0781OC.
    [3]
    WANG L, QIU YL, WANG JS. Advances in research and application of liver organoids[J]. J Clin Hepatol, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.

    王利, 丘倚灵, 王建设. 肝类器官研究及应用进展[J]. 临床肝胆病杂志, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.
    [4]
    WANG DD, SONG J, ZHANG XL. Research advances in the role of gut microbiota in liver diseases[J]. J Clin Hepatol, 2019, 35(9): 2120-2123. DOI: 10.3969/j.issn.1001-5256.2019.09.053.

    王丹丹, 宋佳, 张晓岚. 肠道菌群在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2019, 35(9): 2120-2123. DOI: 10.3969/j.issn.1001-5256.2019.09.053.
    [5]
    XING BM, GUO N, NING HH, et al. Sepsis liver damage and autophagy[J/CD]. Chin J Liver Dis (Electronic Version), 2021, 13(3): 37-41. DOI: 10.3969/j.issn.1674-7380.2021.03.006.

    邢博民, 郭娜, 宁海慧, 等. 脓毒症肝损伤与自噬[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(3): 37-41. DOI: 10.3969/j.issn.1674-7380.2021.03.006.
    [6]
    KOBASHI H, TOSHIMORI J, YAMAMOTO K. Sepsis-associated liver injury: Incidence, classification and the clinical significance[J]. Hepatol Res, 2013, 43(3): 255-266. DOI: 10.1111/j.1872-034X.2012.01069.x.
    [7]
    MARSHALL JC. New translational research provides insights into liver dysfunction in sepsis[J]. PLoS Med, 2012, 9(11): e1001341. DOI: 10.1371/journal.pmed.1001341.
    [8]
    FUCHS M, SANYAL AJ. Sepsis and cholestasis[J]. Clin Liver Dis, 2008, 12(1): 151-172, ix. DOI: 10.1016/j.cld.2007.11.002.
    [9]
    CHIAO YA, ZHANG H, SWEETWYNE M, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice[J]. Elife, 2020, 9: e55513. DOI: 10.7554/eLife.55513.
    [10]
    YANG L, ZHAO K, CALINGASAN NY, et al. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity[J]. Antioxid Redox Signal, 2009, 11(9): 2095-2104. DOI: 10.1089/ars.2009.2445.
    [11]
    TALBERT EE, SMUDER AJ, MIN K, et al. Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant[J]. J Appl Physiol (1985), 2013, 115(4): 529-538. DOI: 10.1152/japplphysiol.00471.2013.
    [12]
    SZETO HH, LIU S, SOONG Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury[J]. J Am Soc Nephrol, 2011, 22(6): 1041-1052. DOI: 10.1681/ASN.2010080808.
    [13]
    WU J, HAO S, SUN XR, et al. Elamipretide (SS-31) ameliorates isoflurane-induced long-term impairments of mitochondrial morphogenesis and cognition in developing rats[J]. Front Cell Neurosci, 2017, 11: 119. DOI: 10.3389/fncel.2017.00119.
    [14]
    ALLEN ME, PENNINGTON ER, PERRY JB, et al. The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats[J]. Commun Biol, 2020, 3(1): 389. DOI: 10.1038/s42003-020-1101-3.
    [15]
    ZHANG XT, LIU JZ, LI P, et al. Research progress of mitophagy in sepsis[J]. China Med Herald, 2021, 18(10): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202110011.htm

    张欣桐, 刘景卓, 李盼, 等. 线粒体自噬在脓毒症中的研究进展[J]. 中国医药导报, 2021, 18(10): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202110011.htm
    [16]
    SUN XD, YAN YH, ZHANG YT, et al. Effects of Xuebijing injection on oxidative stress and early inflammatory factors in rats with sepsis induced liver injury[J]. Chin J Mod Appl Pharm, 2016, 33(10): 1255-1259. DOI: 10.13748/j.cnki.issn1007-7693.2016.10.008.

    孙雪东, 严一核, 张亦婷, 等. 血必净对脓毒症肝损伤大鼠氧化应激及炎症状态的影响[J]. 中国现代应用药学, 2016, 33(10): 1255-1259. DOI: 10.13748/j.cnki.issn1007-7693.2016.10.008.
    [17]
    ZHAO W, XU Z, CAO J, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice[J]. J Neuroinflammation, 2019, 16(1): 230. DOI: 10.1186/s12974-019-1627-9.
    [18]
    SMUDER AJ, ROBERTS BM, WIGGS MP, et al. Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness[J]. Oncotarget, 2020, 11(38): 3502-3514. DOI: 10.18632/oncotarget.27748.
    [19]
    HAO ZH, HUANG Y, WANG MR, et al. SS31 ameliorates age-related activation of NF-κB signaling in senile mice model, SAMP8[J]. Oncotarget, 2017, 8(2): 1983-1992. DOI: 10.18632/oncotarget.14077.
    [20]
    BUTLER J, KHAN MS, ANKER SD, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial[J]. J Card Fail, 2020, 26(5): 429-437. DOI: 10.1016/j.cardfail.2020.02.001.
    [21]
    KARAA A, HAAS R, GOLDSTEIN A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy[J]. Neurology, 2018, 90(14): e1212-e1221. DOI: 10.1212/WNL.0000000000005255.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (633) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return